Eli Lilly and Company (NYSE:LLY) Shares Acquired by C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors

C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors increased its position in shares of Eli Lilly and Company (NYSE:LLY) by 14.4% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,393 shares of the company’s stock after purchasing an additional 175 shares during the period. C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors’ holdings in Eli Lilly and Company were worth $1,234,000 at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. Sovereign Financial Group Inc. raised its stake in shares of Eli Lilly and Company by 3.8% in the 3rd quarter. Sovereign Financial Group Inc. now owns 683 shares of the company’s stock worth $605,000 after buying an additional 25 shares in the last quarter. Strategic Wealth Partners Ltd. raised its position in Eli Lilly and Company by 4.0% in the third quarter. Strategic Wealth Partners Ltd. now owns 11,942 shares of the company’s stock worth $10,580,000 after acquiring an additional 455 shares in the last quarter. Rockingstone Advisors LLC lifted its holdings in Eli Lilly and Company by 24.5% in the 3rd quarter. Rockingstone Advisors LLC now owns 305 shares of the company’s stock valued at $270,000 after acquiring an additional 60 shares during the last quarter. Hoxton Planning & Management LLC boosted its position in shares of Eli Lilly and Company by 17.0% during the 3rd quarter. Hoxton Planning & Management LLC now owns 1,358 shares of the company’s stock valued at $1,203,000 after purchasing an additional 197 shares in the last quarter. Finally, Gratus Wealth Advisors LLC grew its stake in shares of Eli Lilly and Company by 33.7% in the 3rd quarter. Gratus Wealth Advisors LLC now owns 1,721 shares of the company’s stock worth $1,546,000 after purchasing an additional 434 shares during the last quarter. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several analysts recently commented on LLY shares. Morgan Stanley reissued an “overweight” rating and set a $1,106.00 target price on shares of Eli Lilly and Company in a research note on Tuesday, August 27th. BMO Capital Markets raised their price objective on Eli Lilly and Company from $1,001.00 to $1,101.00 and gave the stock an “outperform” rating in a research note on Friday, August 9th. Jefferies Financial Group lifted their target price on Eli Lilly and Company from $994.00 to $1,015.00 and gave the stock a “buy” rating in a report on Monday, June 24th. Citigroup began coverage on Eli Lilly and Company in a report on Friday, September 13th. They set a “buy” rating and a $1,060.00 target price for the company. Finally, Truist Financial reissued a “buy” rating and issued a $1,000.00 price target (up previously from $892.00) on shares of Eli Lilly and Company in a research note on Tuesday, June 25th. Three investment analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $977.35.

Eli Lilly and Company Trading Up 0.7 %

Eli Lilly and Company stock opened at $919.91 on Thursday. Eli Lilly and Company has a 12 month low of $547.61 and a 12 month high of $972.53. The company has a quick ratio of 0.87, a current ratio of 1.11 and a debt-to-equity ratio of 1.74. The stock has a market cap of $874.29 billion, a P/E ratio of 135.48, a P/E/G ratio of 2.78 and a beta of 0.42. The company’s fifty day simple moving average is $904.41 and its 200-day simple moving average is $850.31.

Eli Lilly and Company (NYSE:LLY) last issued its earnings results on Thursday, August 8th. The company reported $3.92 EPS for the quarter, beating analysts’ consensus estimates of $2.64 by $1.28. Eli Lilly and Company had a return on equity of 67.52% and a net margin of 18.86%. The firm had revenue of $11.30 billion for the quarter, compared to the consensus estimate of $9.83 billion. As a group, sell-side analysts forecast that Eli Lilly and Company will post 16.49 EPS for the current fiscal year.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.